LifeMD (LFMD) Q4 2025 earnings review
Pure-Play Transition Complete, But Top-Line Growth is Decelerating
LifeMD closed out 2025 with a clean balance sheet—$36.8M in cash and zero debt—following its WorkSimpli divestiture, cementing its identity as a pure-play telehealth platform. While Q4 delivered a solid $4.8M in Adjusted EBITDA and an 87% gross margin, the broader top-line narrative requires close monitoring. Despite management highlighting a 16% YoY increase in active subscribers, telehealth revenue growth has decelerated aggressively from 70% YoY in Q1 2025 to just 4% in Q4. More critically, Q1 2026 guidance indicates a reversal, projecting a YoY revenue decline and a steep $4-5M Adjusted EBITDA loss to fund a land grab in the fiercely competitive GLP-1 market.
🐂 Bull Case
By eliminating its debt and stockpiling $36.8M in cash, LifeMD has the financial runway to stomach short-term CAC spikes and aggressively acquire patients during the critical oral GLP-1 rollout.
Over 80% of new weight management patients are initiating branded therapy, insulating the company from FDA crackdowns on cheap compounders and improving long-term patient quality.
🐻 Bear Case
Active subscribers grew 16% YoY to 322k, but Q4 revenue grew only 4%, and Q1 2026 guidance implies a 7.5% revenue decline vs Q1 2025. This signals severe revenue-per-user compression.
After stringing together positive EBITDA quarters, Q1 2026 guides to a $4-5M loss due to 'front-loaded' acquisition costs, highlighting how expensive growth has become in the GLP-1 space.
⚖️ Verdict: 🔴
Bearish-leaning. While the balance sheet is fortress-like and the strategic pivot is logical, the collapsing revenue growth rate and return to cash-burning customer acquisition raise serious questions about unit economics and market saturation.
Key Themes
The Subscriber vs. Revenue Disconnect
Management touted 'record patient sign-ups' and a 16% YoY increase in active telehealth subscribers (to 322,872). However, this directly contradicts the top-line reality: telehealth revenue sequentially decelerated from $52.4M in Q1 to $46.8M in Q4. Furthermore, Q1 2026 revenue guidance ($48.5M midpoint) implies a roughly 7.5% YoY contraction against Q1 2025. This severe disconnect strongly indicates that Average Revenue Per User (ARPU) is falling, likely due to a shift toward lower-tier memberships or intense pricing pressure.
Profitability Reversing on CAC Surge
After achieving a record $4.8M Adjusted EBITDA in Q4 (10% margin), Q1 2026 guidance calls for a sudden reversal to a $4M-$5M loss. Management attributes this to 'front-loaded patient acquisition investment' as GLP-1 sign-ups doubled. While investing in LTV is standard, swinging from a $4.8M profit to a $4.5M loss in a single quarter highlights extreme Customer Acquisition Cost (CAC) volatility and the intense competition to capture the weight-loss market.
Strategic Launch of Oral Wegovy
LifeMD successfully launched oral Wegovy subsequent to year-end, which serves as a major driver for patients deterred by injectable therapies. Management noted that over 80% of new weight management patients are initiating on branded therapies, positioning the company as a premium provider rather than relying on the regulatory grey area of compounded GLP-1s.
Macro Tailwinds: Medical Benefits Expansion
The company's medical benefits infrastructure is on track to cover approximately 220 million Americans by the second quarter of 2026. This is a critical macro enabler, as expanded commercial and Medicare coverage for GLP-1 medications shifts the burden from cash-pay to insurance, massively expanding the total addressable market and reducing churn associated with out-of-pocket costs.
Fortress Balance Sheet Fuels the Next Phase
The WorkSimpli divestiture entirely transformed LifeMD's risk profile. The company exited 2025 with $36.8 million in cash and zero debt—a massive reversal from carrying roughly $18M in debt a year ago. This financial strength allows them to absorb the guided Q1 EBITDA losses to aggressively capture market share without returning to capital markets.
Other KPIs
Accelerating. Gross margin expanded to 87% from 81% in the prior-year period. This was primarily driven by a favorable revenue mix shift following the divestiture of the non-core WorkSimpli business, leaving the higher-margin pure-play telehealth and pharmacy operations.
Stable and strong. Up from $32.6 million at the end of 2024, despite fully paying down debt during the year. This liquidity provides vital coverage for the aggressive Q1 2026 marketing investments.
Stable. Flat YoY compared to $57.9 million in 2024, demonstrating that the company is achieving overhead cost containment while attempting to scale operations and absorb new clinical verticals.
Guidance
Reversing. While this represents sequential growth from Q4's $46.9M, it implies a ~7.5% YoY contraction against the $52.4M in pure telehealth revenue generated in Q1 2025. This underscores the top-line headwinds the core business is facing.
Reversing. A sharp drop from Q4's $4.8M profit. Management expects this metric to return to profitability by Q2 as customer acquisition costs normalize and early cohorts begin to yield recurring revenue.
Accelerating. Implies 13% to 19% YoY growth against the 2025 baseline. Management expects to exit the year with an annualized run-rate exceeding $250M, heavily reliant on momentum from GLP-1s and the women's health platform in the back half of the year.
Stable. In line with the $15.3M generated in 2025. Given the heavy expected loss in Q1, achieving this full-year target will require exceptional margin expansion in Q3 and Q4, targeting an exit run-rate of $25M.
Key Questions
ARPU Compression
With active subscribers growing 16% YoY but Q1 2026 revenue guidance implying a 7.5% YoY decline, how much has ARPU compressed, and what is the new normalized revenue baseline per user?
Customer Acquisition Cost ROI
The Q1 EBITDA loss of $4-5M highlights massive CAC pressure. What specific retention metrics or LTV models give you confidence that this front-loaded spend on branded GLP-1 patients will yield a profitable return by Q2?
Insurance Margin Impact
As the medical benefits infrastructure expands to 220 million covered lives, how will the shift from cash-pay to insurance-reimbursed care impact the 87% gross margin profile?